Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Kiniksa Pharmaceuticals International

31/10/2023 13:32

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 17 cents per share.
    * Revenue fell 32.4% to $67.05 million from a year ago;
analysts
expected $64.45 million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kiniksa Pharmaceuticals Ltd shares had fallen by 9.7% this
quarter and gained 4.7% so far this year.
    * The company reported a quarterly loss of $13.86 million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $24.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
October 31 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.17          -0.20          Missed
 Jun. 30 2023      -0.17          0.21           Beat
 Mar. 31 2023      -0.21          -0.18          Beat
 Dec. 31 2022      -0.23          0.06           Beat